The current regulatory landscape for the development of oligonucleotide drugs may lead companies to perform a variety of
small molecule-focussed ADME studies in support of filing packages. The aim of this workshop is for member company
scientists to discuss and exchange ideas and experience of oligonucleotide ADME related challenges (active participation
is expected). Asking the question, if the current activities are suitable for these modalities, and should science-driven
decisions on development of such molecules be implemented more in the industry.